DE:6XP Stock Latest News
Company AnnouncementsXspray Pharma Rights Issue Subscription Period Starts1d ago
Company AnnouncementsXspray Publishes Disclosure Document for Approximately SEK 90 Million Rights Issue6d ago
Company AnnouncementsXspray Pharma Announces 2027 AGM Nomination Committee1w ago
Company AnnouncementsXspray Pharma Approves SEK 90 Million Rights Issue1w ago
Company AnnouncementsXspray Pharma Faces Dasynoc Regulatory Delay as Funding Plans Advance1w ago
Company AnnouncementsFDA Begins Follow-Up Inspection at Xspray Manufacturer1w ago
Company AnnouncementsXspray Pharma to Showcase Commercial Oncology Strategy at Gothenburg Investor Update2M ago
Company AnnouncementsXspray Pharma to Hold Investor Update Alongside Key Leukemia Conference2M ago
Company AnnouncementsXspray Pharma Schedules Call After FDA Response on Lead Cancer Drug Dasynoc3M ago
Company AnnouncementsXspray Pharma Gets FDA Complete Response Letter on Dasynoc, Speeds Manufacturing for 2026 Resubmission3M ago
Company AnnouncementsXspray Pharma Bolsters Finances as FDA Decisions Loom for Nilopki and Dasynoc3M agoCompany AnnouncementsXspray Pharma Advances FDA Reviews for Nilopki and Dasynoc Amid Manufacturing Checks4M ago
Company AnnouncementsXspray Pharma Hit by FDA Setback on Nilopki but Keeps HyNap Strategy on Track5M ago
Company AnnouncementsXspray Pharma Staff Fully Take Up Warrants as Key U.S. Oncology Launches Near5M ago
Company AnnouncementsXspray Pharma AGM Approves Incentive Programs and New Share Issue Mandate6M ago
Company AnnouncementsXspray Pharma Boosts Share Capital After Oversubscribed Rights Issue6M ago
Company AnnouncementsXspray Pharma Secures Funding and FDA Momentum as Losses Narrow in Q1 20266M agoCompany AnnouncementsXspray Pharma Raises SEK 113 Million in Oversubscribed Rights and Over-Allotment Issues7M ago
Company AnnouncementsXspray Wins FDA Nod on Nilopki Name, Sets Stage for Dual CML Drug Launch in U.S.7M ago



